AGIO vs. NVO

Last updated Jun 23, 2026

AGIO (Agios Pharmaceuticals, Inc.) and NVO (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — AGIO in Biotechnology, NVO in Drug Manufacturers - General. Over the past 10 years, AGIO returned -2.29%/yr vs 8.27%/yr for NVO. At a 0.22 correlation, their price movements are largely independent.

Performance

AGIO vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Agios Pharmaceuticals, Inc. (AGIO) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, AGIO achieves a 28.95% return, which is significantly higher than NVO's -6.67% return. Over the past 10 years, AGIO has underperformed NVO with an annualized return of -2.29%, while NVO has yielded a comparatively higher 8.27% annualized return.

AGIO

• 1D: 2.75%
• 1M: 24.73%
• YTD: 28.95%
• 6M: 40.68%
• 1Y: 2.01%
• 3Y*: 9.41%
• 5Y*: -9.05%
• 10Y*: -2.29%

NVO

• 1D: 6.23%
• 1M: 2.05%
• YTD: -6.67%
• 6M: -1.28%
• 1Y: -34.91%
• 3Y*: -14.58%
• 5Y*: 4.55%
• 10Y*: 8.27%

*Multi-year figures are annualized to reflect compound growth (CAGR)

AGIO vs. NVO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
AGIO Agios Pharmaceuticals, Inc.	28.95%	-17.16%	47.55%	-20.69%	-14.57%	-24.14%	-9.26%	3.56%	-19.35%	37.00%
NVO Novo Nordisk A/S	-6.67%	-39.22%	-15.93%	54.84%	22.66%	63.52%	23.33%	28.70%	-12.98%	52.92%

Correlation

The correlation between AGIO and NVO is 0.25, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.25
Correlation (3Y) Calculated over the trailing 3-year period	0.20
Correlation (5Y) Calculated over the trailing 5-year period	0.19
Correlation (10Y) Calculated over the trailing 10-year period	0.20
Correlation (All Time) Calculated using the full available price history since Jul 24, 2013	0.22

Fundamentals

Market Cap AGIO : $2.06B NVO : $204.11B
EPS AGIO : -$7.25 NVO : DKK 27.42
PS Ratio AGIO : 30.98 NVO : 4.06
PB Ratio AGIO : 1.86 NVO : 6.55
Total Revenue (TTM) AGIO : $66.05M NVO : DKK 327.80B
Gross Profit (TTM) AGIO : $59.47M NVO : DKK 268.30B
EBITDA (TTM) AGIO : -$443.16M NVO : DKK 181.54B

Return for Risk

AGIO vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AGIO

AGIO Risk / Return Rank: 46
AGIO Sharpe Ratio Rank: 43
AGIO Sortino Ratio Rank: 46
AGIO Omega Ratio Rank: 55
AGIO Calmar Ratio Rank: 43
AGIO Martin Ratio Rank: 42

NVO

NVO Risk / Return Rank: 15
NVO Sharpe Ratio Rank: 13
NVO Sortino Ratio Rank: 16
NVO Omega Ratio Rank: 15
NVO Calmar Ratio Rank: 15
NVO Martin Ratio Rank: 17

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AGIO vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Agios Pharmaceuticals, Inc. (AGIO) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	AGIO	NVO	Difference
Sharpe ratio: Return per unit of total volatility	0.03	-0.67	+0.70
Sortino ratio: Return per unit of downside risk	0.60	-0.71	+1.32
Omega ratio: Gain probability vs. loss probability	1.13	0.90	+0.23
Calmar ratio: Return relative to maximum drawdown	0.04	-0.71	+0.75
Martin ratio: Return relative to average drawdown	0.07	-1.13	+1.20

AGIO vs. NVO - Sharpe Ratio Comparison

The current AGIO Sharpe Ratio is 0.03, which is higher than the NVO Sharpe Ratio of -0.67. The chart below compares the historical Sharpe Ratios of AGIO and NVO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

AGIO vs. NVO - Drawdown Comparison

The maximum AGIO drawdown since its inception was -87.36%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for AGIO and NVO.

Drawdown Indicators

	AGIO	NVO	Difference
Max Drawdown Largest peak-to-trough decline	-87.36%	-74.70%	-12.66%
Max Drawdown (1Y) Largest decline over 1 year	-50.89%	-49.17%	-1.72%
Max Drawdown (3Y) Largest decline over 3 years	-63.76%	-74.70%	+10.94%
Max Drawdown (5Y) Largest decline over 5 years	-70.68%	-74.70%	+4.02%
Max Drawdown (10Y) Largest decline over 10 years	-82.86%	-74.70%	-8.16%
Current Drawdown Current decline from peak	-74.00%	-66.66%	-7.34%
Average Drawdown Average peak-to-trough decline	-58.88%	-17.81%	-41.07%
Ulcer Index Depth and duration of drawdowns from previous peaks	28.94%	32.54%	-3.60%

Volatility

AGIO vs. NVO - Volatility Comparison

Agios Pharmaceuticals, Inc. (AGIO) has a higher volatility of 16.13% compared to Novo Nordisk A/S (NVO) at 11.74%. This indicates that AGIO's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AGIO	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.13%	11.74%	+4.39%
Volatility (6M) Calculated over the trailing 6-month period	44.61%	38.27%	+6.34%
Volatility (1Y) Calculated over the trailing 1-year period	75.21%	52.05%	+23.16%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	58.93%	38.45%	+20.48%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	56.91%	32.60%	+24.31%

Dividends

AGIO vs. NVO - Dividend Comparison

AGIO has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.93%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
AGIO Agios Pharmaceuticals, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVO Novo Nordisk A/S	3.93%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Financials

Frequently Asked Questions

Can I hold both AGIO and NVO in my portfolio?

AGIO and NVO have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, AGIO or NVO?

AGIO has higher volatility (16.13%) compared to NVO (11.74%). In terms of maximum drawdown, AGIO dropped -87.36% vs NVO's -74.70%.

Which has better risk-adjusted returns?

AGIO currently has the higher Sharpe Ratio (0.03 vs -0.67), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.